Ceritinib (ceritinib) is developed and produced by which company? Drug R&D background and manufacturers

Ceritinib (Ceritinib), trade name Ceritinib, is a targeted treatment drug for non-small cell lung cancer (NSCLC) ALK gene mutations. The drug is developed and produced by Swiss pharmaceutical giant Novartis (Novartis). As a second-generation ALK inhibitor, ceritinib was launched to overcome the resistance problem after crizotinib treatment. It has shown stronger ability to inhibit ALK rearranged tumors in clinical trials, and has been approved for marketing in many countries and regions.

Novartis has strong R&D capabilities in the field of targeted cancer therapy and is a global leader in the innovation of molecularly targeted drugs. Ceritinib is one of Novartis' important achievements in the development of targeted drugs for lung cancer, and it is also the company's next blockbuster anti-cancer drug after Gleevec (imatinib). Ceritinib was first granted accelerated approval by the U.S. FDA in 2014 for the treatment of ALK-positive advanced non-small cell lung cancer, and has since been approved in Europe, Asia and other countries and regions.

In terms of production, the original drug of ceritinib is mainly responsible for the production bases of Novartis, including its pharmaceutical factories in Switzerland, Germany and other regions, ensuring that the quality of the drugs meets international standards. The original drug has complete research and development data support, clinical verification and strict production control. Although the price is relatively high, it brings new treatment hope to many patients with advanced lung cancer around the world.

Currently, ceritinib has been approved for marketing in mainland China, but due to its high price and not being fully covered by medical insurance, some patients are also concerned about the existence of generic versions. It should be noted that if there are quality and efficacy risks of generic drugs from informal channels on the market, patients should try to choose regular drugs approved by the national drug regulatory department and use the drugs rationally under the guidance of oncologists to obtain safe and effective treatment results.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib